Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
EyePoint Pharmaceuticals Inc Company Overview 5
EyePoint Pharmaceuticals Inc Company Snapshot 5
EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview 5
EyePoint Pharmaceuticals Inc – Pipeline Analysis Overview 7
EyePoint Pharmaceuticals Inc – Key Facts 7
EyePoint Pharmaceuticals Inc – Major Products and Services 8
EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage 9
EyePoint Pharmaceuticals Inc Ongoing Clinical Trials by Trial Status 11
EyePoint Pharmaceuticals Inc Pipeline Products Overview 12
Durasert – Back Of Eye Disease 12
Durasert – Back Of Eye Disease Product Overview 12
Durasert – Front Of Eye Disease 13
Durasert – Front Of Eye Disease Product Overview 13
Durasert – Knee Osteoarthritis 14
Durasert – Knee Osteoarthritis Product Overview 14
Durasert Latanoprost Implant 15
Durasert Latanoprost Implant Product Overview 15
DURASERT With TKI – Wet AMD 16
DURASERT With TKI – Wet AMD Product Overview 16
Next Gen Duraset – Posterior Segment Uveitis 17
Next Gen Duraset – Posterior Segment Uveitis Product Overview 17
Tethadur System 18
Tethadur System Product Overview 18
YUTIQ 19
YUTIQ Product Overview 19
YUTIQ Clinical Trial 20
EyePoint Pharmaceuticals Inc – Key Competitors 21
EyePoint Pharmaceuticals Inc – Key Employees 22
EyePoint Pharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
EyePoint Pharmaceuticals Inc, Recent Developments 24
Jul 11, 2018: EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists 24
Jul 10, 2018: BioArctic receives regulatory approval in Finland for Phase 1/2 study in patients with Complete Spinal Cord Injury 24
Jun 26, 2018: EyePoint Pharmaceuticals Names Goran Ando As Board Director 25
May 16, 2018: EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S. 25
May 08, 2018: EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results 26
Apr 18, 2018: EyePoint Pharmaceuticals YUTIQ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 27
Mar 19, 2018: pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert Three-Year Treatment for Posterior Segment Uveitis 27
Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines 28
Feb 07, 2018: pSivida’s Second Phase 3 Study for Durasert Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months 29
Jan 08, 2018: pSivida Submits New Drug Application for Durasert Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA 29
Appendix 30
Methodology 30
About GlobalData 33
Contact Us 33
Disclaimer 33
EyePoint Pharmaceuticals Inc Pipeline Products and Ongoing Clinical Trials Overview 5
EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type 6
EyePoint Pharmaceuticals Inc Pipeline Products by Indication 6
EyePoint Pharmaceuticals Inc Ongoing Clinical Trials by Trial Status 6
EyePoint Pharmaceuticals Inc, Key Facts 7
EyePoint Pharmaceuticals Inc, Major Products and Services 8
EyePoint Pharmaceuticals Inc Number of Pipeline Products by Development Stage 9
EyePoint Pharmaceuticals Inc Pipeline Products Summary by Development Stage 10
EyePoint Pharmaceuticals Inc Ongoing Clinical Trials by Trial Status 11
EyePoint Pharmaceuticals Inc Ongoing Clinical Trials Summary 11
Durasert - Back Of Eye Disease - Product Status 12
Durasert - Back Of Eye Disease - Product Description 12
Durasert - Front Of Eye Disease - Product Status 13
Durasert - Front Of Eye Disease - Product Description 13
Durasert - Knee Osteoarthritis - Product Status 14
Durasert - Knee Osteoarthritis - Product Description 14
Durasert Latanoprost Implant - Product Status 15
Durasert Latanoprost Implant - Product Description 15
DURASERT With TKI - Wet AMD - Product Status 16
DURASERT With TKI - Wet AMD - Product Description 16
Next Gen Duraset - Posterior Segment Uveitis - Product Status 17
Next Gen Duraset - Posterior Segment Uveitis - Product Description 17
Tethadur System - Product Status 18
Tethadur System - Product Description 18
YUTIQ - Product Status 19
YUTIQ - Product Description 19
YUTIQ - A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye 20
YUTIQ - A Phase III, Multi-national, Multi-center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye 20
EyePoint Pharmaceuticals Inc, Key Employees 22
EyePoint Pharmaceuticals Inc, Subsidiaries 23
Glossary 32
List of Figures
EyePoint Pharmaceuticals Inc Pipeline Products by Equipment Type 6
EyePoint Pharmaceuticals Inc Pipeline Products by Development Stage 9
EyePoint Pharmaceuticals Inc Ongoing Clinical Trials by Trial Status 11